Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Deal To Help Propel Aurobindo's Revenues To $2 Billion In Three Years

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - With fifteen manufacturing sites under its belt and a comprehensive outsourcing deal with Pfizer, India's Aurobindo Pharma expects to see a huge bounce in its revenues from the present $800 million to over $2 billion in a span of three years

You may also be interested in...



With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted

MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad

With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted

MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad

Buoyed By Big Offers And Repository of Data, Aurobindo Branches Out Into CRAMS Business With Aurosource

HYDERABAD, India - Athough a relatively late entrant into the contract research and manufacturing space in India, Aurobindo Pharma with its new logo "Nothing compromised" thinks there is still enough room to forge credible relationships with Western companies for newly floated CRAMS unit Aurosource

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel